Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.

Allan Lipton, Harold Harvey, Lois Witters, Samuel Kerr, Kathryn Legore, Cynthia Campbell

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Unresectable pancreatic cancer has few therapeutic options and a dismal prognosis. Cyclooxygenase-2 (COX-2) expression is increased at the RNA and protein levels in most human pancreatic cancers. The purpose of this trial was to determine whether the addition of a COX-2 inhibitor to chemotherapy was beneficial. To date, 11 patients with inoperable pancreatic cancer have been treated with the combination of gemcitabine (Gemzar), irinotecan (Camptosar), and celecoxib (Celebrex) at 400 mg orally twice daily. Encouraging pain relief, improvement in performance status, and decreases in CA 19-9 and carcinoembryonic antigen levels have been observed.

Original languageEnglish (US)
Pages (from-to)43-45
Number of pages3
JournalOncology (Williston Park, N.Y.)
Volume18
Issue number14 Suppl 14
StatePublished - Jan 1 2004

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.'. Together they form a unique fingerprint.

  • Cite this

    Lipton, A., Harvey, H., Witters, L., Kerr, S., Legore, K., & Campbell, C. (2004). Gemcitabine/Irinotecan/celecoxib in pancreatic cancer. Oncology (Williston Park, N.Y.), 18(14 Suppl 14), 43-45.